PRRT2 and cancer: The rest of the hits are made up of one, or a few members of, estrogen receptor modulators, protein kinase C (PKC)/mitogen-activated protein kinase (MAPK) inhibitors, calcium channel/P-glycoprotein blockers, anti-cancer agents, and anti-fungals.